Fenghuan Sun
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Neoadjuvant PD-1 Blockade Tislelizumab (BGB-A317) in Combination With Etoposide and Platinum-Based Chemotherapy for Limited-Disease Small Cell Lung Cancer.
Journal: MedComm
Published: December 16, 2025
Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I‒III small-cell lung cancer: a phase 2 trial (LungMate-005).
Journal: Cell discovery
Published: February 12, 2025
Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial.
Journal: BMC medicine
Published: December 01, 2024
Segmentectomy for non-peripheral and peripheral small-sized non-small-cell lung cancer.
Journal: Interdisciplinary cardiovascular and thoracic surgery
Published: October 11, 2024
Longitudinal relationship between posttraumatic growth and distress in lung cancer patients during neoadjuvant immunotherapy.
Journal: International journal of clinical and health psychology : IJCHP
Published: September 25, 2024
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study.
Journal: Signal transduction and targeted therapy
Published: October 30, 2023
Pulmonary Function Recovery and Displacement Patterns After Anatomic Segmentectomy vs Lobectomy.
Journal: The Annals of thoracic surgery
Published: June 01, 2023
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.
Journal: Nature communications
Published: December 16, 2022
Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing.
Journal: Genome medicine
Published: April 19, 2022
Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
Journal: BMC medicine
Published: March 14, 2022
Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer.
Journal: The Annals of thoracic surgery
Published: July 31, 2021
Last Updated: 09/26/2026